Full-Time

Facilities Associate 2/3

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$75k - $95k/yr

San Diego, CA, USA

In Person

Category
Facilities Operations (2)
,
Requirements
  • Bachelor’s degree in Engineering, Life Sciences, or related field preferred; equivalent hands-on experience in GMP environments will be considered.
  • 3–5 years of experience in a GMP-regulated facilities or equipment maintenance role, ideally in biotech or pharmaceutical manufacturing.
  • Strong understanding of GMP compliance, calibration standards, and equipment lifecycle management.
  • Demonstrated ability to manage vendors, prioritize competing tasks, and work independently with minimal supervision.
  • Proficiency in equipment tracking and maintenance systems; experience with CMMS or QMS software a plus.
  • Excellent written and verbal communication skills for clear documentation and cross-functional collaboration.
  • Exceptional organizational skills and attention to detail, with a proactive and solutions-oriented mindset.
Responsibilities
  • Own and manage the calibration and preventive maintenance program for GMP-critical equipment, ensuring accuracy, compliance, and timely execution.
  • Lead the induction of new controlled assets into the inventory and maintenance tracking systems.
  • Independently execute and improve daily, weekly, and monthly facilities operations to support manufacturing and laboratory readiness.
  • Develop, revise, and optimize calibration and preventive maintenance schedules in alignment with operational needs and regulatory standards.
  • Create and maintain accurate equipment documentation, including maintenance logs, procedures, and records.
  • Schedule and coordinate maintenance and calibration work with external vendors and internal teams, ensuring minimal disruption to production and lab activities.
  • Drive vendor qualification processes in partnership with Quality Assurance, including documentation review and audit support.
  • Collaborate with Quality Engineering to ensure timely completion and closure of equipment work orders, deviations, and change controls.
  • Act as a key contact for troubleshooting and resolving equipment issues, coordinating repairs and root cause analysis with vendors.
  • Initiate and support quality records, including deviations, CAPAs, and change controls that impact GMP operations and facilities infrastructure.
  • Identify and recommend process improvements to enhance facility efficiency, compliance, and reliability.
Desired Qualifications
  • None
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval expected August 22, 2026 enables rapid market entry and revenue generation.
  • Manufacturing facility passed FDA pre-license inspection; capacity scales to 2,500 patients annually.
  • $318 million cash runway funds operations through Q4 2027 post-launch commercialization.

What critics are saying

  • FDA rejects Deramiocel BLA again by August 22, 2026 due to manufacturing deficiencies.
  • Sarepta's Elevidys gene therapy captures 80% DMD market share within 24 months.
  • EVP insider share sales signal management doubts; stock drops 50% pre-approval decision.

What makes Capricor Therapeutics unique

  • First therapy delivering statistically significant upper limb function improvement in DMD.
  • Rare Pediatric Disease Designation qualifies Capricor for valuable Priority Review Voucher.
  • Exclusive US and Japan commercialization partnership with Nippon Shinyaku validates market potential.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Capricor Therapeutics who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...